Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders-Reference-Cited by-同舟云学术

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

Published:2021-06-12 Issue:3 Volume:110 Page:808-815
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharmacol Ther

Author:

Hopkins Seth C.¹,Wilkinson Scott¹,Corriveau Taryn J.¹,Nishikawa Hiroyuki²,Nakamichi Keiko²,Loebel Antony¹,Koblan Kenneth S.¹

Affiliation:

1. Sunovion Pharmaceuticals Inc Marlborough Massachusetts USA

2. Drug Research Division Sumitomo Dainippon Pharma Co., Ltd. Osaka Japan

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2282

Reference52 articles.

1. Clinical and theoretical implications of 5‐HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia;Kapur S.;Am. J. Psych.,1999

2. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol

3. Antipsychotic-Induced Extrapyramidal Side Effects in Bipolar Disorder and Schizophrenia

4. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder

5. Serotonergic agents in the treatment of acute neuroleptic-induced akathisia

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enrichment using speech latencies improves treatment effect size in a clinical trial of bipolar depression;Psychiatry Research;2024-10

2. Evaluating speech latencies during structured psychiatric interviews as an automated objective measure of psychomotor slowing;Psychiatry Research;2024-10

3. A clinical trial inclusion criteria to enrich for patients presenting with canonical symptom structure in bipolar depression;Contemporary Clinical Trials;2024-10

4. Discovery and Model‐Informed Drug Development of a Controlled‐Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain;Clinical Pharmacology & Therapeutics;2024-05-31

5. NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2022;Medicinal Chemistry Reviews;2023-11-16